Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Boceprevir for HCV in patients with HIV: where next?

Osinusi A, Naggie S.

Lancet Infect Dis. 2013 Jul;13(7):563-4. doi: 10.1016/S1473-3099(13)70162-2. No abstract available.

PMID:
23768748
2.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators..

Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X.

PMID:
23768747
3.

Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.

Rivero-Juarez A, Lopez-Cortes LF, Girón-Gonzalez JA, Pineda JA, Rivero A; Grupo Andaluz para Estudio de Hepatitis Víricas (HEPAVIR) de Sociedad Andaluza de Enfermedades Infecciosas..

Lancet Infect Dis. 2014 Jan;14(1):13-4. doi: 10.1016/S1473-3099(13)70359-1. No abstract available.

PMID:
24355031
4.

HCV therapy with daclatasvir, PEG-IFN, and RBV after boceprevir-based therapy failure post-liver transplantation in hyper-IgM syndrome.

Reddy KR, Wirjosemito A, Pavri TM, Sinese L.

Transplantation. 2014 Apr 27;97(8):e47-8. doi: 10.1097/TP.0000000000000076. No abstract available.

PMID:
24732900
5.

A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.

Maticic M, Luznik Z, Stepec S, Popovic P, Snedec N, Poljak M, Stanisavljevic D.

J Clin Gastroenterol. 2014 May-Jun;48(5):464-5. doi: 10.1097/MCG.0000000000000037. No abstract available.

PMID:
24275712
6.

Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.

Mandorfer M, Steiner S, Schwabl P, Payer BA, Aichelburg MC, Lang G, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T.

J Infect Dis. 2015 Mar 1;211(5):729-35. doi: 10.1093/infdis/jiu516.

7.

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.

Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, Bacon BR, Niederau C, Sherman M, Goteti V, Sings HL, Barnard RO, Howe JA, Pedicone LD, Burroughs MH, Brass CA, Albrecht JK, Poordad F.

Clin Gastroenterol Hepatol. 2013 Jan;11(1):81-87.e4; quiz e5. doi: 10.1016/j.cgh.2012.10.006.

PMID:
23064222
8.

[Current indications for triple therapy in hepatitis C virus infection].

Molina Pérez E, Fernández Castroagudín J, Domínguez Muñoz E.

Gastroenterol Hepatol. 2012 Apr;35(4):266-77. doi: 10.1016/j.gastrohep.2012.01.003. Spanish.

PMID:
22410706
9.

Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.

Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz E, Yoshida EM, Galati J, Luketic V, McCone J, Jacobson I, Marcellin P, Muir AJ, Poordad F, Pedicone LD, Albrecht J, Brass C, Howe AY, Colvard LY, Helmond FA, Deng W, Treitel M, Wahl J, Bronowicki JP.

J Hepatol. 2014 Apr;60(4):748-56. doi: 10.1016/j.jhep.2013.12.013.

PMID:
24362076
10.

Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.

Soriano V, Sherman KE, Rockstroh J, Dieterich D, Back D, Sulkowski M, Peters M.

AIDS. 2011 Nov 28;25(18):2197-208. doi: 10.1097/QAD.0b013e32834bbb90. Review.

PMID:
21866039
11.

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.

Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, DiNubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP.

Hepatology. 2012 Aug;56(2):567-75. doi: 10.1002/hep.25865.

PMID:
22619063
12.

Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.

Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P.

Ann Rheum Dis. 2014 May;73(5):831-7. doi: 10.1136/annrheumdis-2012-202770.

13.

Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.

Vierling JM, Zeuzem S, Poordad F, Bronowicki JP, Manns MP, Bacon BR, Esteban R, Flamm SL, Kwo PY, Pedicone LD, Deng W, Dutko FJ, DiNubile MJ, Koury KJ, Helmond FA, Wahl J, Bruno S.

J Hepatol. 2014 Aug;61(2):200-9. doi: 10.1016/j.jhep.2014.03.022.

PMID:
24747798
14.
15.

[Triple combination treatment of chronic hepatitis C].

Husa P.

Vnitr Lek. 2012 Jul-Aug;58(7-8):588-90. Czech.

PMID:
23067190
16.

New therapies for hepatitis C virus infection.

Bacon BR, Khalid O.

Mo Med. 2011 Jul-Aug;108(4):255-9.

PMID:
21905441
17.

Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.

Gordon SC, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ.

J Clin Gastroenterol. 2014 May-Jun;48(5):435-43. doi: 10.1097/MCG.0000000000000000.

PMID:
24177376
18.

Hepatitis C therapy update.

Casey LC, Lee WM.

Curr Opin Gastroenterol. 2012 May;28(3):188-92. doi: 10.1097/MOG.0b013e3283528e1e. Review.

PMID:
22476156
19.

Boceprevir: a protease inhibitor for the treatment of hepatitis C.

Chang MH, Gordon LA, Fung HB.

Clin Ther. 2012 Oct;34(10):2021-38. doi: 10.1016/j.clinthera.2012.08.009. Review.

PMID:
22975763
20.

[Dual infection with HIV and HCV. Focus on antiviral therapy].

[No authors listed]

MMW Fortschr Med. 2001 Oct 4;143(40):54. German. No abstract available.

PMID:
11692848
Items per page

Supplemental Content

Support Center